Shares of Enzo Biochem, Inc. (NYSE:ENZ) reached a new 52-week low on Thursday . The company traded as low as $3.48 and last traded at $3.52, with a volume of 4725 shares traded. The stock had previously closed at $3.77.

ENZ has been the subject of a number of recent research reports. ValuEngine upgraded Enzo Biochem from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. TheStreet downgraded Enzo Biochem from a “c-” rating to a “d+” rating in a research report on Wednesday.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Tuesday, October 16th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.06). Enzo Biochem had a negative net margin of 9.86% and a negative return on equity of 13.25%. The company had revenue of $24.46 million during the quarter.

A number of hedge funds have recently made changes to their positions in the business. Marathon Capital Management lifted its position in Enzo Biochem by 3.6% in the second quarter. Marathon Capital Management now owns 356,804 shares of the medical research company’s stock valued at $1,851,000 after purchasing an additional 12,400 shares during the last quarter. Highbridge Capital Management LLC lifted its position in Enzo Biochem by 50.3% in the first quarter. Highbridge Capital Management LLC now owns 38,340 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 12,836 shares during the last quarter. Cadence Capital Management LLC lifted its position in Enzo Biochem by 12.1% in the second quarter. Cadence Capital Management LLC now owns 172,844 shares of the medical research company’s stock valued at $897,000 after purchasing an additional 18,656 shares during the last quarter. A.R.T. Advisors LLC bought a new stake in Enzo Biochem in the first quarter valued at approximately $115,000. Finally, Hartford Investment Management Co. bought a new stake in Enzo Biochem in the second quarter valued at approximately $118,000. Hedge funds and other institutional investors own 67.75% of the company’s stock.

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

Recommended Story: Diversification For Individual Investors

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.